Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis, and its news flow reflects ongoing progress in this specialized area of drug development. Company announcements frequently describe advances in its pipeline of small molecule nucleotide binding domain 1 (NBD1) stabilizers and complementary CFTR modulators designed to improve CFTR protein function.
News items for SION often cover key clinical milestones, such as initiation of the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis, and the Phase 1 trial assessing SION-451 in dual combinations with SION-2222 and SION-109 in healthy volunteers. Updates may include information on trial design, target patient populations, measures of CFTR function such as sweat chloride levels, and the rationale for combining NBD1 stabilizers with existing therapies.
Investors and observers can also find press releases on Phase 1 data, including reports that SION-719 and SION-451 were generally well tolerated and exceeded target exposure levels, as well as preclinical findings that NBD1 stabilizers increased the half-life of F508del-CFTR protein to levels seen with wild-type CFTR. Additional news highlights Sionna’s participation in scientific meetings like the North American Cystic Fibrosis Conference and appearances at healthcare and investor conferences.
This SION news page aggregates these disclosures, allowing readers to follow developments in Sionna’s CF-focused programs, track clinical and preclinical data releases, and monitor corporate updates that the company furnishes through press releases and related communications.
Sionna Therapeutics (SION) presented clinical analyses and new preclinical cystic fibrosis data at the 2026 North American Cystic Fibrosis Conference.
PreciSION CF, evaluating SION-719 added to Trikafta, did not achieve its key activity endpoint. Post hoc analyses excluding three participants with drug-exposure patterns consistent with dosing non-adherence showed a mean placebo-adjusted sweat chloride reduction of 8.6 mmol/L. Lower exposure to all three Trikafta components and a potential interaction with ivacaftor complicated interpretation. In laboratory studies, NBD1-stabilizer combinations improved CFTR protein trafficking and function up to wild-type levels in cells from donors with one or two F508del copies. Sionna expects the SION-451 + SION-2222 AscenSION CF Phase 2a trial to begin in the first quarter of 2027.
Sionna Therapeutics (SION) plans to advance its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2a proof-of-concept trial, expected to start in the first quarter of 2027.
The open-label trial will enroll adults with cystic fibrosis (CF) homozygous for F508del who will switch from Trikafta to SION-451 + SION-2222 for 28 days, with assessments of sweat chloride, safety, and pharmacokinetics. The move follows post hoc analyses of the PreciSION CF Phase 2a trial of SION-719, which originally showed modest placebo-adjusted sweat chloride changes of about -1.0 to -1.1 mmol/L but, after excluding three PK outliers, showed a mean placebo-adjusted reduction of -8.6 mmol/L using a secondary baseline method.
Sionna is discontinuing investment in SION-719 as an add-on to standard of care and has chosen SION-451 + SION-2222 as its preferred dual combination based on Phase 1 safety, tolerability, PK, and target exposure coverage results. The company will implement a workforce reduction of approximately 46% and other cost-saving actions, expects about $6.4 million in restructuring and related charges, and reported $268.3 million in cash, cash equivalents, and marketable securities at the end of Q2 2026, estimating its cash runway now extends into the second half of 2029.
Sionna Therapeutics (Nasdaq: SION) reported topline data from two cystic fibrosis programs and provided a corporate update. The Phase 2a PreciSION CF trial of SION-719 added to Trikafta did not meet its key activity endpoint in sweat chloride reduction, and Sionna will not advance SION-719 as an add-on to standard of care.
The Phase 1 healthy volunteer trial of SION-451 dual combinations met safety, tolerability, and pharmacokinetic objectives, with SION-451 + SION-2222 selected as the preferred combination. According to Sionna, SION-719 and the dual regimens were generally well tolerated. The company ended Q2 with about $268.3 million in cash, cash equivalents, and marketable securities and plans to take actions to preserve capital while evaluating next steps for SION-451.
Sionna Therapeutics (Nasdaq: SION) reported second quarter 2026 results and clinical progress for its cystic fibrosis (CF) pipeline. The PreciSION CF Phase 2a proof-of-concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care has completed enrollment and remains on track to deliver topline data in summer 2026, assessing safety, pharmacokinetics and CFTR function via sweat chloride.
The Phase 1 trial of NBD1 stabilizer SION-451 in proprietary dual combinations with CFTR correctors SION-2222 and SION-109 in healthy volunteers is also expected to report topline data this summer. According to Sionna, encore clinical and nonclinical data for SION-719 and SION-451 were presented at the 49th European Cystic Fibrosis Conference, showing nonclinical evidence that NBD1 stabilizers can increase F508del-CFTR protein half-life up to wild-type levels alone or with complementary modulators.
For the quarter ended June 30, 2026, research and development expenses were $21.9 million and general and administrative expenses were $10.6 million, leading to a net loss of $29.9 million (basic and diluted net loss per share of $0.66). Cash, cash equivalents and marketable securities totaled $268.3 million, which Sionna expects will fund operations into 2028.
Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharma focused on cystic fibrosis, will participate in two June 2026 investor conferences.
Management presents at the Jefferies Global Healthcare Conference on June 3, 2026, at 12:15 p.m. ET and a Goldman Sachs Global Healthcare fireside chat on June 10, 2026, at 10:00 a.m. ET. Live webcasts and replays will be available in the company’s Investors section online.
Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharmaceutical company focused on cystic fibrosis, will join the 2026 RBC Capital Markets Global Healthcare Conference.
Management will participate in a fireside chat on May 20, 2026 at 2:05 p.m. ET, with a live webcast and replay available via the company’s investor website.
Sionna Therapeutics (Nasdaq:SION) reported Q1 2026 results and CF pipeline progress. Enrollment in the PreciSION CF Phase 2a trial of SION-719 is complete, and a Phase 1 dual-combination trial of SION-451 is ongoing, with topline data for both expected in summer 2026.
Q1 2026 R&D expenses were $19.0M, G&A expenses $10.6M, and net loss $26.8M. Cash, cash equivalents and marketable securities totaled $289.9M at March 31, 2026, expected to fund operations into 2028.
Sionna Therapeutics (Nasdaq: SION) announced completion of enrollment in the PreciSION CF Phase 2a proof-of-concept trial testing SION-719, a first-in-class NBD1 stabilizer added to Trikafta® in adults homozygous for F508del. Topline data are anticipated in summer 2026.
The randomized, double-blind, placebo-controlled, crossover study will evaluate safety, tolerability, pharmacokinetics, and change in sweat chloride as a measure of CFTR function. The trial enrolled at multiple sites including the CF Foundation Therapeutics Development Network.
Sionna Therapeutics (Nasdaq: SION) said management will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026. The meetings provide investor access to management to discuss clinical progress in cystic fibrosis programs and corporate strategy.
Sionna Therapeutics (Nasdaq: SION) reported fourth-quarter and full-year 2025 results and a pipeline update. Cash, cash equivalents and marketable securities totaled $310.3 million as of December 31, 2025, expected to fund operations into 2028.
Ongoing Phase 2a PreciSION CF trial of SION-719 and a Phase 1 dual-combination trial of SION-451 remain on track with topline data anticipated in mid-2026. Company reported higher net loss and increased general and administrative expenses for 2025.